Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: Application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients

Investigational New Drugs

Volumn 32, Issue 5, 2014, Pages 985-994

  Du Rieu, Quentin Chalret ^a,b   Fouliard, Sylvain ^a   White Koning, Mélanie ^b   Kloos, Ioana ^a   Chatelut, Etienne ^b,c   Chenel, Marylore ^a  

^a IRIS Institut de Recherches Internationales Servier   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c Institut Universitaire du Cancer de Toulouse   (France)

Author keywords

Abexinostat; Disease progression; PKPD model; Recommended dose; Simulation; Thrombocytopenia

Indexed keywords

ABEXINOSTAT; ANTINEOPLASTIC AGENT; BENZOFURAN DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

BIOLOGICAL MODEL; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; HUMAN; MAXIMUM TOLERATED DOSE; NEOPLASMS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; BENZOFURANS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MAXIMUM TOLERATED DOSE; MODELS, BIOLOGICAL; NEOPLASMS; THROMBOCYTOPENIA;

EID: 84930699565     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0118-1     Document Type: Article

References (40)

1. Eisenhauer EA, O'Dwyer PJ, Christian M, Humphrey JS (2000) Phase I clinical trial design in cancer drug development. J Clin Oncol 18:684-692
2. Le Tourneau C, Faivre S, Raymond E, Dieras V (2007) Phase I cancer trials methodology. Bull Cancer 94:943-951
3. Ratain MJ, Mick R, Schilsky RL, Siegler M (1993) Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst 85:1637-1643
4. Cannistra SA (2008) Challenges and pitfalls of combining targeted agents in phase I studies. J Clin Oncol 26:3665-3667
5. Le Tourneau C, Lee JJ, Siu LL (2009) Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 101:708-720
6. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138-1147
7. Storer BE (1989) Design and analysis of phase I clinical trials. Biometrics 45:925-937
8. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van GM, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
9. Storer BE (2001) An evaluation of phase I clinical trial designs in the continuous dose-response setting. Stat Med 20:2399-2408
10. Von Hoff DD, Turner J (1991) Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs 9:115-122
11. Bhatia M, Davenport V, Cairo MS (2007) The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes. Leuk Lymphoma 48:9-15
12. Elting LS, Rubenstein EB, Martin CG, Kurtin D, Rodriguez S, Laiho E, Kanesan K, Cantor SB, Benjamin RS (2001) Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol 19:1137-1146
13. Elting LS, Martin CG, Kurtin DJ, Cantor SB, Rubenstein EB, Rodriguez S, Kanesan K, Vadhan-Raj S, Benjamin RS (2002) The bleeding risk index: a clinical prediction rule to guide the prophylactic use of platelet transfusions in patients with lymphoma or solid tumors. Cancer 94:3252-3262
14. Belt RJ, Leite C, Haas CD, Stephens RL (1978) Incidence of hemorrhagic complications in patients with cancer. JAMA 239:2571-2574
15. Dutcher JP, Schiffer CA, Aisner J, O'Connell BA, Levy C, Kendall JA, Wiernik PH (1984) Incidence of thrombocytopenia and serious hemorrhage among patients with solid tumors. Cancer 53:557-562
16. Gaydos, L. A., Freireich, E. J., Mantel, N. (3-5-1962) The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 266:905-909
17. Bishton MJ, Harrison SJ, Martin BP, McLaughlin N, James C, Josefsson EC, Henley KJ, Kile BT, Prince HM, Johnstone RW (2011) Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood 117:3658-3668
18. Marks PA, Xu WS (2009) Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 107:600-608
19. Matsuoka H, Unami A, Fujimura T, Noto T, Takata Y, Yoshizawa K, Mori H, Aramori I, Mutoh S (2007) Mechanisms of HDAC inhibitor-induced thrombocytopenia. Eur J Pharmacol 571:88-96
20. Prince HM, Bishton MJ, Harrison SJ (2009) Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15:3958-3969
21. Ali A, Bluteau O, Messaoudi K, Palazzo A, Boukour S, Lordier L, Lecluse Y, Rameau P, Kraus-Berthier L, Jacquet-Bescond A, Lelievre H, Depil S, Dessen P, Solary E, Raslova H, Vainchenker W, Plo I, Debili N (2013) Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and - independent mechanisms. Cell Death Dis 4:e738
22. Chalret du Rieu Q, Fouliard S, Jacquet-Bescond A, Robert R, Kloos I, Depil S, Chatelut E, Chenel M (2013) Application of hematological toxicity modeling in clinical development of abexinostat (S-78454, PCI-24781). a new histone deacetylase inhibitor. Pharm Res 30:2640-2653
23. Faries D (1994) Practical modifications of the continual reassessment method for phase I cancer clinical trials. J Biopharm Stat 4:147-164
24. He W, Liu J, Binkowitz B, Quan H (2006) A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials. Stat Med 25:2027-2042
25. Smith TL, Lee JJ, Kantarjian HM, Legha SS, Raber MN (1996) Design and results of phase I cancer clinical trials: three year experience at M.D. anderson cancer center. J Clin Oncol 14:287-295
26. Fouliard S, Robert R, Jacquet-Bescond A, du Rieu QC, Balasubramanian S, Loury D, Loriot Y, Hollebecque A, Kloos I, Soria JC, Chenel M, Depil S (2013) Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I. Eur J Cancer 49:2791-2797
27. Sheiner LB, Beal SL (1980) Evaluation of methods for estimating population pharmacokinetics parameters. I. michaelis-menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 8: 553-571
28. Zhang L, Beal SL, Sheiner LB (2003) Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn 30:387-404
29. Quartino AL, Friberg LE, Karlsson MO (2012) A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model. Invest New Drugs 30:833-845
30. Van Kesteren C, Zandvliet AS, Karlsson MO, Mathot RA, Punt CJ, Armand JP, Raymond E, Huitema AD, Dittrich C, Dumez H, Roche HH, Droz JP, Ravic M, Yule SM, Wanders J, Beijnen JH, Fumoleau P, Schellens JH (2005) Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs 23:225-234
31. Brendel K, Comets E, Laffont C, Laveille C, Mentre F (2006) Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 23:2036-2049
32. Brendel K, Comets E, Laffont C, Mentre F (2010) Evaluation of different tests based on observations for external model evaluation of population analyses. J Pharmacokinet Pharmacodyn 37:49-65
33. Lavielle M, Bleakley K (2011) Automatic data binning for improved visual diagnosis of pharmacometric models. J Pharmacokinet Pharmacodyn 38:861-871
34. Post TM, Freijer JI, Ploeger BA, Danhof M (2008) Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn 35:185-202
35. Hitchcock, I. S., Kaushansky, K. (2014) Thrombopoietin from beginning to end. Br J Haematol.
36. Kaushansky K (2003) Thrombopoietin: a tool for understanding thrombopoiesis. J Thromb Haemost 1:1587-1592
37. Comets E, Brendel K, Mentre F (2008) Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 90:154-166
38. Ji Y, Li Y, Nebiyou BB (2007) Dose-finding in phase I clinical trials based on toxicity probability intervals. Clin Trials 4:235-244
39. Ji Y, Wang SJ (2013) Modified toxicity probability interval design: a safer and more reliable method than the 3+3 design for practical phase I trials. J Clin Oncol 31:1785-1791
40. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20:4713-4721